News Releases

GAITHERSBURG, MD . and SHANGHAI , July 6, 2022 /PRNewswire/ -- I-Mab (" I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will host its 2022 Research and

GAITHERSBURG, Md. and SHANGHAI , June 23, 2022 /PRNewswire/ -- I-Mab (" I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies

SHANGHAI and GAITHERSBURG, Md. , June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner

SHANGHAI and GAITHERSBURG, Md. , May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinical

-  Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity -  Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort -  Results indicate CD73 expression correlates with clinical

SHANGHAI and GAITHERSBURG, MD . , May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8 a.m.

SHANGHAI and GAITHERSBURG, Md. , May 5, 2022 /PRNewswire/ -- I-Mab (" I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provided updates on its status under the Holding

SHANGHAI, China and GAITHERSBURG, MD. , April 29, 2022 (PRNewswire) — I-Mab (“I-Mab” or the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company has filed its annual

-  Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO -  Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of I-Mab's innovative pipeline as CMO SHANGHAI and

SHANGHAI and GAITHERSBURG, Md. , March 31, 2022 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company's key shareholders including CBC